Report topline results for the pivotal bioequivalence study of RENAZORB
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 14 Nov 2022
- Due
- 31 Dec 2022
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to have topline data by year’s end”
What we found
Evidence strength A What the grades mean
The company did not report topline results by the end of 2022; later filings indicate the pivotal study was not initiated until December 2023.
-
A Unicycive Therapeutics, Inc. 10-K filed 2024-03-28
“This study was initiated in December 2023 and the topline data is expected at the end of Q2, 2024.” ✓ confirmed on the page
Market reaction: the shares moved -4.7% against the S&P 500 over the three sessions around the disclosure (27 Mar 2024 to 2 Apr 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- RENAZORB pivotal bioequivalence study topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002776 · Corrections policy